Invitae launches first CE-IVD cancer testing kits in Europe
pharmafile | February 16, 2022 | News story | Research and Development |Â Â Â
Invitae, leading medical genetics company, announced the availability of FusionPlex Dx and LiquidPlex Dx in Europe.
With this development, the company provides CE-IVD products to enable European pathologists and oncologists to efficiently provide vital information, in a timely manner, to guide cancer therapy for patients.
Invitae’s FusionPlex Dx and LiquidPlex Dx allow comprehensive genomic profiling (CGP) and companion diagnostic (CDx) use for solid tumour neoplasms, including non-small cell lung cancer (NSCLC) in tissue biopsy, and where tissue is a limiting factor.
“Increasing patient access to content on our instrument fleet through partnerships such as those with Invitae speaks to our mission to improve human health by unlocking the power of the genome,” said Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina. “We congratulate Invitae on its first CE-IVD cancer testing kits, a significant milestone.”
“This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine,” said Vishal Sikri, President of Oncology at Invitae. “Our best in class FusionPlex and LiquidPlex tests will enable more patients access to the right cancer therapies at the right time, which is especially critical in Europe where the majority of molecular testing is performed locally in decentralised hospital settings.”
“With Invitae’s simplified workflow and reporting solutions, both tests will enable any facility with sequencing technology, combined with our solutions, to accurately profile solid tumorus using tissue or blood samples for therapy selection,” added Sikri. “Precision medicine has increasingly delivered better outcomes for many cancer patients over the last several years. Molecular pathology has never been more important as the fight against cancer shifts towards precision oncology and targeted therapies based on genomic testing. Yet globally, access to the exponentially increasing therapy options is not guaranteed.”
Lina Adams
